Use of Long-Acting Lipoglycopeptide Antibiotics—Beyond Convenience
JAMA Internal Medicine · 01.06.2026 · 186 (6) · 762
DOI: 10.1001/jamainternmed.2026.0977 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, erschienen am 01.06.2026. Verfasst von Raneem H Pallotta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Utah Health, Salt Lake City. Die Arbeit nennt 8 Literaturangaben.
Abstract (Originalsprache)
This Clinical Insights summarizes the pharmacological characteristics of dalbavancin and oritavancin and evaluates the clinical evidence supporting their use in infections beyond acute bacterial skin and skin structure infections for general internal medicine clinicians.
Autor:innen und Institutionen
- Department of Pharmacy, University of Utah Health, Salt Lake City.
- Division of Infectious Diseases, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.
Zitieren
APA
Pallotta, R. H., & Spivak, E. S. (2026). Use of Long-Acting Lipoglycopeptide Antibiotics—Beyond Convenience. JAMA Internal Medicine, 186(6), 762. https://doi.org/10.1001/jamainternmed.2026.0977
Vancouver
Pallotta RH, Spivak ES. Use of Long-Acting Lipoglycopeptide Antibiotics—Beyond Convenience. JAMA Internal Medicine. 2026;186(6):762. doi:10.1001/jamainternmed.2026.0977
BibTeX
@article{Pallotta2026,
author = {Pallotta, Raneem H and Spivak, Emily S},
title = {Use of Long-Acting Lipoglycopeptide Antibiotics—Beyond Convenience},
journal = {JAMA Internal Medicine},
year = {2026},
volume = {186},
number = {6},
pages = {762},
doi = {10.1001/jamainternmed.2026.0977}
}
EUVIMED